FDA Approves Addition of Survival Data to Gilteritinib Label for Refractory AML with a FLT3 Mutation

May 30

2019

The Food and Drug Administration approved the addition of overall survival data in labeling for gilteritinib (XOSPATA, Astellas Pharma US, Inc.), indicated for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

Citations

APA

American Society of Hematology. (2019).
FDA Approves Addition of Survival Data to Gilteritinib Label for Refractory AML with a FLT3 Mutation.
Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/fda-approves-addition-survival-data-gilteritinib-label-refractory-aml-flt3-mutation.

Chicago

American Society of Hematology.
"FDA Approves Addition of Survival Data to Gilteritinib Label for Refractory AML with a FLT3 Mutation." Hematology.org.
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/fda-approves-addition-survival-data-gilteritinib-label-refractory-aml-flt3-mutation
(label-accessed December 14, 2024).

MLA

"American Society of Hematology."
FDA Approves Addition of Survival Data to Gilteritinib Label for Refractory AML with a FLT3 Mutation, 14 Dec. 2024 ,
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/fda-approves-addition-survival-data-gilteritinib-label-refractory-aml-flt3-mutation.

Citation Manager Formats

BibLaTeX
Bookends
EasyBib
EndNote
Mendeley
Papers
RIS
Ref Manager
RefWorks
Zotero

Help ASH Build an Inclusive Hematology Community!

ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.

How Can You Help?

Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!

Update Access to Demographic Information Learn About Our Mission